K Shiue, A Cerra-Franco, V Verma, M Arbab, M P Langer, C Deig, M E Tharp Ii, P A Anthony, M Shan, S Althouse, Y Zang, G K Bartlett, J A Holmes, C DesRosiers, P G Maxim, D Frye, F M Kong, J Y Jin, G Watson, R C Zellars, T Lautenschlaeger
PURPOSE/OBJECTIVE(S): We aimed to evaluate the safety of and maximum tolerated dose (MTD) for 5-fraction stereotactic ablative radiotherapy (SABR) for early-stage lung squamous cell carcinoma (SCC), for which local failure rates appears higher than that of early-stage adenocarcinomas. MATERIALS/METHODS: A single institution phase I study was conducted in pathologically confirmed early-stage lung SCC. The 3+3 design involved 4 dose levels of 11, 12, 13, and 14 Gy x 5 fractions delivered every other day (dose levels DL1, DL2, DL3, and DL4, respectively)...
November 1, 2021: International Journal of Radiation Oncology, Biology, Physics